Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ULBI Transcript
Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Unknown11-18
The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.
Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.
Ultralife Corporation (NASDAQ:ULBI) Q1 2025 Earnings Call Transcript
Unknown5-11
The earnings call reveals mixed signals. While revenue grew 21% YoY, operating income and EPS decreased due to increased expenses and acquisition costs. Strong government-defense sales were offset by declines in other segments. The Q&A highlighted concerns over tariffs and vague management responses, but also noted confidence in transformational projects and steady medical markets. Despite no share repurchase program, the backlog and working capital indicate demand and liquidity. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement in either direction.
Ultralife Corporation (ULBI) Q1 2025 Earnings Call Transcript
Unknown5-9
Despite a strong revenue increase and optimistic guidance, the lack of a share repurchase program and concerns about tariffs, military spending, and product acceptance pose risks. The Q&A highlights potential operational challenges and unclear management responses. These factors, combined with decreased net income and operating income, suggest a mixed outlook, leading to a neutral rating. Without a market cap, the stock's reaction remains uncertain, but the absence of a share repurchase plan and potential operational issues are likely to temper any positive financial news.
ULBI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
